A

Allergy and Asthma Clinical Research | Walnut Creek, CA

Research site

(Unclaimed)

Location

370 N. Wiget Lane, Suite 210, Walnut Creek, California, United States of America

Site insights

Top conditions

Top treatments

Ligelizumab

azelastine hydrochloride

fluticasone propionate

Lanadelumab

azelastineHcl

azelastine Hcl

Indacaterol

Omalizumab

NOC-110

Remibrutinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 25 total trials

Locations recently updated

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Enrolling

Asthma

Drug: Placebo

Drug: Rocatinlimab

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and...

Enrolling

Primary Immunodeficiency Diseases (PID)

Biological: TAK-881

Biological: HYQVIA

Long-term Extension Study of Ligelizumab in Food Allergy

This is an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who have completed a ligelizumab Phase III st...

Active, not recruiting

Food Allergy

Drug: Ligelizumab 120 mg

Drug: Ligelizumab 240 mg

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

A study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed al...

Enrolling

Allergy, Peanut

Drug: placebo

Drug: remibrutinib

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough (ASPIRE)

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalatio...

Enrolling

Refractory or Unexplained Chronic Cough

Drug: NOC-110

Other: Placebo